#### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors, and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

## For all that apply, please note where in the manuscript the required information is provided.

# Materials:

| Newly created materials   | indicate where provided: page no/section/legend)              | n/a   |
|---|---|-------|
| The manuscript includes a dedicated "materials<br>availability statement" providing transparent<br>disclosure about availability of newly created<br>materials including details on how materials can be<br>accessed and describing any restrictions on access. | Methods part  |       |
| Antibodies  | indicate where provided: page no/section/legend)              | n/a   |
| For commercial reagents, provide supplier name, catalogue number and <u>RRID</u> , if available.  | Methods/part 2 and part 5                                     |       |
| DNA and RNA sequences   | indicate where provided: page no/section/legend)              | n/a   |
| Short novel DNA or RNA including primers, probes:<br>Sequences should be included or deposited in a<br>public repository.   | Methods/part 4-5  |       |
| Cell materials  | indicate where provided: page no/section/legend               | n/a   |
| <b>Cell lines:</b> Provide species information, strain.   | malcale where provided, page no/section/legend                | 11/ d |
| Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID.   | Methods/part 3  |       |
| <b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.   | Methods/part 3  |       |
| Experimental animals  | indicate where provided: page no/section/legend)              | n/a   |
| Laboratory animals or Model organisms: Provide<br>species, strain, sex, age, genetic modification status.<br>Provide accession number in repository OR supplier<br>name, catalog number, clone number, OR RRID.   | No animals' or model organisms' experiments were conducted    | n/a   |
| Animal observed in or captured from the field:<br>Provide species, sex, and age where possible.   | No animal observed in or captured from the field              | n/a   |
| Plants and microbes   | indicate where provided: page no/section/legend)              | n/a   |
| <b>Plants:</b> provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens).   | No plants' experiment was conducted                           | n/a   |
| <b>Microbes:</b> provide species and strain, unique accession number if available, and source.  | No microbes' experiment was conducted                         | n/a   |
| Human research participants   | indicate where provided: page no/section/legend) or           | n/a   |
| If collected and within the bounds of privacy<br>constraints report on age, sex and gender or<br>ethnicity for all study participants.  | state if these demographics were not collected Methods/part 1 |       |

## Design:

| Study protocol   | indicate where provided: page no/section/legend) | n/a |
|--|--|-----|
| If study protocol has been pre-registered, provide<br>DOI. For clinical trials, provide the trial registration<br>number <b>OR</b> cite DOI. | No study protocol has been pre-registered        | n/a |

| Laboratory protocol  | indicate where provided: page no/section/legend) | n/a |
|--|--|-----|
| Provide DOI <b>OR</b> other citation details if detailed step-<br>by-step protocols are available. | Methods section described the protocol clearly.  |     |

| Experimental study design (statistics details)                          |  |     |
|---|--|-----|
| For in vivo studies: State whether and how the following have been done | indicate where provided: page no/section/legend. If it could have been done, but was not, write not done | n/a |
| Sample size determination   | It's an in vitro study.  | n/a |
| Randomisation   | lt's an in vitro study.  | n/a |
| Blinding  | lt's an in vitro study.  | n/a |
| Inclusion/exclusion criteria  | lt's an in vitro study.  | n/a |

| Sample definition and in-laboratory replication                    | indicate where provided: page no/section/legend | n/a |
|--|---|-----|
| State number of times the experiment was replicated in laboratory. | Methods/part 5                                  |     |
| Define whether data describe technical or biological replicates.   | Methods/part 5                                  |     |

| Ethics   | indicate where provided: page no/section/legend | n/a |
|--|---|-----|
| <b>Studies involving human participants:</b> State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.     | Methods/part 1                                  |     |
| Studies involving experimental animals: State<br>details of authority granting ethics approval (IRB or<br>equivalent committee(s), provide reference number<br>for approval. | No experimental animals were involved in study. | n/a |
| <b>Studies involving specimen and field samples:</b> State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.   | Methods/part 1                                  | n/a |

| Dual Use Research of Concern (DURC)  | indicate where provided: page no/section/legend | n/a |
|--|---|-----|
| If study is subject to dual use research of concern<br>regulations, state the authority granting approval<br>and reference number for the regulatory approval. | Study was not dual use research.                | n/a |

#### Analysis:

| Attrition   | indicate where provided: page no/section/legend | n/a |
|---|---|-----|
| Describe whether exclusion criteria were<br>preestablished. Report if sample or data points were<br>omitted from analysis. If yes report if this was due to<br>attrition or intentional exclusion and provide<br>justification. | Methods/part 1                                  |     |

| Statistics  | indicate where provided: page no/section/legend | n/a |
|---|---|-----|
| Describe statistical tests used and justify choice of |   |     |
| tests.  | Methods/part 7                                  |     |
|   |   |     |

| Data availability   | indicate where provided: page no/section/legend | n/a |
|---|---|-----|
| For newly created and reused datasets, the manuscript includes a data availability statement that provides details for access or notes restrictions on access.    | Footnote section                                |     |
| If newly created datasets are publicly available,<br>provide accession number in repository <b>OR</b> DOI <b>OR</b><br>URL and licensing details where available. | Not including any newly created datasets.       | n/a |
| If reused data is publicly available provide accession<br>number in repository <b>OR</b> DOI <b>OR</b> URL, <b>OR</b> citation.                                   | Not including any reused datasets.              | n/a |

| Code availability   | indicate where provided: page no/section/legend | n/a |
|---|---|-----|
| For all newly generated custom computer<br>code/software/mathematical algorithm or re-used<br>code essential for replicating the main findings of<br>the study, the manuscript includes a data availability<br>statement that provides details for access or notes<br>restrictions. | Not applying any code.                          | n/a |
| If newly generated code is publicly available, provide<br>accession number in repository, <b>OR</b> DOI <b>OR</b> URL and<br>licensing details where available. State any<br>restrictions on code availability or accessibility.  | Not including any newly generated code.         | n/a |
| If reused code is publicly available provide accession<br>number in repository <b>OR</b> DOI <b>OR</b> URL, <b>OR</b> citation.   | Not including any reused code.                  | n/a |

## **Reporting**

| Adherence to community standards                    | Yes (indicate where provided: section/paragraph)       | n/a |
|---|--|-----|
| MDAR framework recommends adoption of               |  |     |
| discipline-specific guidelines, established and     |  |     |
| endorsed through community initiatives. Journals    |  |     |
| have their own policy about requiring specific      |  |     |
| guidelines and recommendations to complement        |  |     |
| MDAR.   |  |     |
| State if relevant guidelines (eg., ICMJE, MIBBI,    | ICMJE guidelines were followed, as the journal follows |     |
| ARRIVE) have been followed, and whether a checklist | ICMJE recommendations for publication.                 |     |
| (eg., CONSORT, PRISMA, ARRIVE) is provided with     |  |     |
| the manuscript.                                     |  |     |

Article information: <u>http://dx.doi.org/10.21037/atm-21-596</u>